Celltex Therapeutics has initiated talks with the US Food and Drug Administration (FDA) to conduct a study of adult, autologous mesenchymal stem cells (MSCs) for the treatment of Covid-19 symptoms.
The company assessed the safety and efficacy of MSCs in people with injuries, pain and conditions associated with autoimmune, vascular and other diseases such as pneumonia.
Celltex, in alliance with the Texas A&M University Institute for Regenerative Medicine, evaluated MSCs in Covid-19 patients. Data from this study showed that intravenous administration of clinical-grade human MSCs led to improved functional outcomes.
The editorial titled ‘Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (Covid-19) – Induced Pneumonia’ was published in the Aging and Disease journal.
During the study, intravenous MSCs were found to be safe and effective in treating novel coronavirus patients with pneumonia. The therapy is said to have yielded encouraging data even in elderly patients with severe pneumonia.